Victor Deaton
Family · Hermitage, TNNPI 1205514338
Payments from drug & device makers
Across 591 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- ANI Pharmaceuticals, Inc.$867
- Neurocrine Biosciences, Inc.$684
- SK Life Science, Inc.$676
- Biogen$658
- plus $7K from 36 others
What the payments were for
- Speaking & faculty fees$570%
- Food & beverage$12,54099%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$139
- PURIFIED CORTROPHIN GEL$123
- UBRELVY$120
- XCOPRI$115
- Symbravo$103
How this compares
$12,608 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 23 | $80,021 |
| NuplazidPimavanserin Tartrate | 11 | $59,590 |
| AptiomEslicarbazepine Acetate | 16 | $30,870 |
| Nurtec OdtRimegepant Sulfate | 13 | $17,472 |
| BriviactBrivaracetam | 11 | $16,563 |
| UbrelvyUbrogepant | 12 | $12,464 |
| BrilintaTicagrelor | 12 | $9,652 |
| Rivastigmine | 13 | $4,053 |
| Oxcarbazepine | 37 | $2,756 |
| Levocarnitine | 11 | $2,461 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 43 | $2,142 |
| Levetiracetam | 37 | $1,654 |
| Gabapentin | 107 | $1,185 |
| Memantine Hcl | 43 | $1,097 |
| Lacosamide | 21 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $191 | $80,02123 claims |
| Acadia Pharmaceuticals IncNuplazid | $275 | $59,59011 claims |
| PfizerNurtec Odt | $540 | $17,47213 claims |
| UCB, Inc.Briviact | $1,314 | $16,56311 claims |
| AbbVieUbrelvy | $1,620 | $12,46412 claims |
| AstraZenecaBrilinta | $362 | $9,65212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Hermitage
- April SwonerHermitage$246K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.